Edition:
United States

People: Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

29.38USD
29 Mar 2017
Change (% chg)

$0.54 (+1.87%)
Prev Close
$28.84
Open
$28.84
Day's High
$29.41
Day's Low
$28.61
Volume
250,174
Avg. Vol
434,725
52-wk High
$44.38
52-wk Low
$24.47

Richard, Ronald 

Mr. Ronald B. Richard is Lead Independent Director of Emergent BioSolutions Inc. Mr. Richard has served as the president and chief executive officer of the Cleveland Foundation, the nation’s oldest community foundation, since June 2003. From August 2002 to February 2003, Mr. Richard served as president of Stem Cell Preservation, Inc., a start-up medical research company. After leaving Stem Cell Preservation and prior to joining Emergent BioSolutions, Mr. Richard served as a strategic business advisor for IGEN International, Inc., a biotechnology company. Mr. Richard served as chief operating officer of In-Q-Tel, a venture capital fund that provides technologies to the Central Intelligence Agency, from March 2001 to August 2002. Prior to joining In-Q-Tel, Mr. Richard served in various senior management positions at Matsushita Electric (Panasonic), a consumer electronics company. Mr. Richard is a former U.S. foreign service officer. He served in Osaka/Kobe, Japan and as a desk officer for North Korean, Greek and Turkish affairs at the U.S. Department of State in Washington, D.C. Mr. Richard previously served as chairman of the board of trustees of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. Mr. Richard received an M.A. in international relations from Johns Hopkins University School of Advanced International Studies and a B.A. in history from Washington University. He holds honorary doctorates in humane letters from Notre Dame College and Baldwin Wallace College. We believe Mr. Richard’s qualifications to serve on our board of directors include his past and current industry experience, including his prior senior management positions, including positions in the biotechnology industry.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 427,566
Fiscal Year Total, USD 427,566

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Fuad El-Hibri

2,726,910

Daniel Abdun-Nabi

3,642,930

Robert Kramer

1,511,980

Adam Havey

1,073,360

Ronald Richard

427,566

Kathryn Zoon

--
As Of  30 Dec 2015